Represents potential penetration into ~ 20% of the U.S. institutional market, while broadening access across long-term care and outpatient facilities U.S. losartan market totals $256M annually with ...
Scienture Holdings, Inc. announced GPO agreements for its new drug, Arbli, providing access to over 2,500 healthcare ...
Premier has entered a five-year group purchasing agreement with Premier Infusion and Healthcare Services expected to exceed an estimated $50 million in annual contract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback